- ISIN
- US68062P1066
- CUSIP
- 68062P106
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Nov 19, 2020
Highlights
- Market Cap
- $1.03B
- Enterprise Value
- $977.37M
- EPS (TTM)
- -$2.03
- Gross Profit (TTM)
- -$187.00K
- EBITDA (TTM)
- -$197.79M
- Year Range
- $4.12 - $36.26
- Target Price
- $42.50
- ROA (TTM)
- -34.89%
- ROE (TTM)
- -38.53%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
OLMA Performance Chart
Olema Pharmaceuticals, Inc. (OLMA) is down 60.0% since the beginning of the year. At $10 per share, OLMA is trading 72.4% below its 52-week high of $36. Investors who bought $1,000 worth of OLMA shares 5 years ago would now be looking at an investment worth $375.
Loading charts...
Returns By Period
Olema Pharmaceuticals, Inc. (OLMA) has returned -60.00% so far this year and 142.13% over the past 12 months.
Olema Pharmaceuticals, Inc.
- 1D
- 5.15%
- 1M
- -26.90%
- YTD
- -60.00%
- 6M
- -64.51%
- 1Y
- 142.13%
- 3Y*
- 8.31%
- 5Y*
- -17.80%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
OLMA Monthly Returns History
Based on dividend-adjusted daily data since Nov 19, 2020, OLMA's average daily return is +0.09%, while the average monthly return is +2.92%. At this rate, an investment would double in approximately 2.0 years.
Historically, 41% of months were positive and 59% were negative. The best month was Nov 2025 with a return of +215.7%, while the worst month was Nov 2021 at -67.6%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.
On a daily basis, OLMA closed higher 48% of trading days. The best single day was Nov 18, 2025 with a return of +136.4%, while the worst single day was Nov 30, 2021 at -60.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.88% | -5.91% | -38.39% | -3.35% | -8.47% | -24.18% | -60.00% | ||||||
| 2025 | 4.80% | -28.48% | -13.96% | 37.23% | 2.33% | -19.32% | 20.66% | 6.23% | 79.30% | -8.38% | 215.72% | -11.72% | 328.82% |
| 2024 | -7.06% | -4.91% | -8.71% | -10.16% | -4.82% | 11.78% | 49.35% | -26.98% | 1.19% | -3.43% | -12.23% | -42.39% | -58.45% |
| 2023 | 97.14% | -15.11% | -15.37% | 38.04% | 7.93% | 74.66% | -4.21% | 17.34% | 21.67% | 7.61% | 4.97% | 0.57% | 472.65% |
| 2022 | -31.30% | -27.22% | -8.97% | -40.14% | 12.16% | 42.31% | 23.34% | -21.31% | -30.13% | 36.23% | -23.67% | -14.63% | -73.82% |
| 2021 | -11.71% | -5.96% | -16.88% | -15.46% | -0.32% | 0.07% | -16.08% | 27.43% | -7.89% | -2.03% | -67.59% | 6.97% | -80.53% |
Benchmark Metrics
Olema Pharmaceuticals, Inc. has an annualized alpha of 6.16%, beta of 1.22, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since November 19, 2020.
- This stock participated in 249.46% of S&P 500 Index downside but only 224.93% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 6.16%
- Beta
- 1.22
- R²
- 0.04
- Upside Capture
- 224.93%
- Downside Capture
- 249.46%
Return for Risk
Risk / Return Rank
OLMA ranks 79 for risk / return — better than 79% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Olema Pharmaceuticals, Inc. (OLMA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| OLMA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.14 | ||
| Sortino ratioReturn per unit of downside risk | +0.48 | ||
| Omega ratioGain probability vs. loss probability | 1.41 | 1.37 | +0.04 |
| Calmar ratioReturn relative to maximum drawdown | 1.92 | 2.78 | -0.86 |
| Martin ratioReturn relative to average drawdown | 3.89 | 12.44 | -8.55 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Olema Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Olema Pharmaceuticals, Inc. was 96.26%, occurring on May 11, 2022. The portfolio has not yet recovered.
The current Olema Pharmaceuticals, Inc. drawdown is 81.65%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -96.26%May 2022 | 1y 5mo | — | 5y 6moDec 2020 - now |
2020 correction2020 | -10.74%Nov 2020 | 0s | 7d | 7dNov 2020 - Dec 2020 |
2020 pullback2020 | -0.20%Nov 2020 | 0s | 3d | 3dNov 2020 - Nov 2020 |
Drawdown Indicators
| OLMA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.26% | -56.78% | -39.48% |
Max Drawdown (1Y)Largest decline over 1 year | -74.35% | -9.10% | -65.25% |
Max Drawdown (3Y)Largest decline over 3 years | -82.15% | -18.90% | -63.25% |
Max Drawdown (5Y)Largest decline over 5 years | -93.36% | -25.43% | -67.93% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -81.65% | -1.80% | -79.85% |
Average DrawdownAverage peak-to-trough decline | -74.99% | -10.71% | -64.28% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 36.69% | 2.03% | +34.66% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Olema Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Olema Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for OLMA in comparison with other companies in the Biotechnology industry. Currently, OLMA has a P/B value of 2.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with OLMA
Add Olema Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with OLMA